AUTOLUS THERAPEUTICS PLC's ticker is AUTL and the CUSIP is 05280R100. A total of 67 filers reported holding AUTOLUS THERAPEUTICS PLC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $122,062 | -2.1% | 52,387 | 0.0% | 0.00% | – |
Q2 2023 | $124,681 | -31.5% | 52,387 | -48.3% | 0.00% | – |
Q1 2023 | $181,982 | -10.6% | 101,247 | -5.5% | 0.00% | – |
Q4 2022 | $203,516 | +78.5% | 107,114 | +100.9% | 0.00% | – |
Q3 2022 | $114,000 | -25.5% | 53,317 | -1.1% | 0.00% | – |
Q2 2022 | $153,000 | -49.0% | 53,927 | -25.0% | 0.00% | – |
Q1 2022 | $300,000 | -62.1% | 71,900 | -52.8% | 0.00% | – |
Q4 2021 | $791,000 | +143.4% | 152,372 | +207.4% | 0.00% | – |
Q3 2021 | $325,000 | +122.6% | 49,566 | +125.1% | 0.00% | – |
Q2 2021 | $146,000 | +13.2% | 22,019 | -2.3% | 0.00% | – |
Q1 2021 | $129,000 | -35.8% | 22,534 | 0.0% | 0.00% | – |
Q4 2020 | $201,000 | -28.7% | 22,534 | -7.1% | 0.00% | – |
Q3 2020 | $282,000 | +55.8% | 24,267 | +115.4% | 0.00% | – |
Q2 2020 | $181,000 | +154.9% | 11,268 | -4.9% | 0.00% | – |
Q1 2020 | $71,000 | -57.7% | 11,844 | -6.8% | 0.00% | – |
Q4 2019 | $168,000 | +5.0% | 12,708 | -1.5% | 0.00% | – |
Q3 2019 | $160,000 | – | 12,900 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Syncona Portfolio Ltd | 21,346,829 | $49,738,112 | 74.10% |
TFG Asset Management GP Ltd | 12,000,000 | $27,960,000 | 5.10% |
Paradigm Biocapital Advisors LP | 14,406,782 | $33,567,802 | 2.28% |
Lynx1 Capital Management LP | 1,363,025 | $3,175,848 | 2.10% |
Deep Track Capital, LP | 15,000,000 | $34,950,000 | 1.35% |
Affinity Asset Advisors, LLC | 1,992,466 | $4,642,446 | 1.31% |
DAFNA Capital Management LLC | 928,253 | $2,162,829 | 0.67% |
Frazier Life Sciences Management, L.P. | 3,746,857 | $8,730,177 | 0.58% |
ARMISTICE CAPITAL, LLC | 6,900,000 | $16,077,000 | 0.25% |
Blackstone Inc. | 20,485,611 | $47,731,474 | 0.20% |